These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7938102)

  • 1. Laser aggregometer studies, ATP release and thromboxane B2 release and cAMP concentration of the platelets in nephrotic syndrome.
    Turi S; Bereczki C; Torday C; Havass Z
    Prostaglandins Leukot Essent Fatty Acids; 1994 Jul; 51(1):69-73. PubMed ID: 7938102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of bicarbonate and acetate haemodialysis on platelet cyclic AMP concentration, thromboxane B2 release and aggregation.
    Túri S; Bereczki C; Torday C; Havass Z; Németh M
    Pediatr Nephrol; 1991 May; 5(3):327-31. PubMed ID: 1651098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of erythropoietin on platelet function in uraemic children on haemodialysis.
    Turi S; Soos J; Torday C; Bereczki C; Havass Z
    Pediatr Nephrol; 1994 Dec; 8(6):727-32. PubMed ID: 7696114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome.
    Jackson CA; Greaves M; Patterson AD; Brown CB; Preston FE
    Br J Haematol; 1982 Sep; 52(1):69-77. PubMed ID: 6810912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome.
    Machleidt C; Mettang T; Stärz E; Weber J; Risler T; Kuhlmann U
    Kidney Int; 1989 Dec; 36(6):1119-24. PubMed ID: 2532267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet aggregation, platelet cAMP levels and thromboxane B2 synthesis in patients with diabetes mellitus.
    Chen SY; Yu BJ; Liang YQ; Lin WD
    Chin Med J (Engl); 1990 Apr; 103(4):312-8. PubMed ID: 2167823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in platelet calcium concentration by thromboxane A2 stimulation in patients with nephrotic syndrome of childhood.
    Kobayashi T; Suzuki J; Watanabe M; Suzuki S; Yoshida K; Kume K; Suzuki H
    Nephron; 1997; 77(3):309-14. PubMed ID: 9375825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in platelet sensitivity to thromboxane A2 in pediatric patients with nephrotic syndrome].
    Watanabe M; Suzuki J; Suzuki H
    Nihon Jinzo Gakkai Shi; 1996 Aug; 38(8):356-63. PubMed ID: 8828355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolism of arachidonic acid by platelets in nephrotic syndrome.
    Schieppati A; Dodesini P; Benigni A; Massazza M; Mecca G; Remuzzi G; Livio M; de Gaetano G; Rossi EC
    Kidney Int; 1984 Apr; 25(4):671-6. PubMed ID: 6434788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production.
    Cattaneo M; Tenconi PM; Lecchi A; Mannucci PM
    Thromb Res; 1991 Jun; 62(6):717-24. PubMed ID: 1926062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
    Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome.
    Yoshida N; Aoki N
    Blood; 1978 Nov; 52(5):969-77. PubMed ID: 698401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet effect of the anaesthetic drug propofol: influence of red blood cells and leucocytes.
    De La Cruz JP; Páez MV; Carmona JA; De La Cuesta FS
    Br J Pharmacol; 1999 Dec; 128(7):1538-44. PubMed ID: 10602334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of phentolamine on platelet aggregation, thromboxane B2 production and release reaction.
    Anfossi G; Trovati M; Mularoni E; Lanzio M; Massucco P; Emanuelli G
    Arch Int Pharmacodyn Ther; 1988; 296():144-54. PubMed ID: 2853612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
    Liao CH; Ko FN; Wu CL; Teng CM
    J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of platelet thromboxane formation and phosphoinositides breakdown by diisoeugenol.
    Lin CH; Kuo YH; Lin YL; Teng CM
    J Pharm Pharmacol; 1994 Jan; 46(1):54-7. PubMed ID: 8201527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
    Schrör K; Löbel P; Steinhagen-Thiessen E
    Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced platelet aggregability and thromboxane release after rebleeding in patients with subarachnoid hemorrhage.
    Juvela S; Kaste M
    J Neurosurg; 1991 Jan; 74(1):21-6. PubMed ID: 1984502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levobupivacaine differentially suppresses platelet aggregation by modulating calcium release in a dose-dependent manner.
    Liou JT; Mao CC; Liu FC; Lin HT; Hung LM; Liao CH; Day YJ
    Acta Anaesthesiol Taiwan; 2012 Sep; 50(3):112-21. PubMed ID: 23026170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S; Westwick J; Kakkar VV
    Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.